8-K Announcements
6Material company update
Mar 16, 2026·SEC
Material company update
Mar 12, 2026·SEC
Material company update
Nov 13, 2025·SEC
Elicio Therapeutics, Inc.(ELTX)Earnings, Financials & Key Ratios
ELTX•NASDAQ
$10.45
$186M mkt cap·Price updated May 6, 2026
AboutElicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.Show more
- Revenue$0
- EBITDA-$38M+13.9%
- Net Income-$40M+23.8%
- EPS (Diluted)-2.58+39.3%
- ROE-2418.77%+98.6%
- Debt/Equity3.12
ELTX Key Insights
Elicio Therapeutics, Inc. (ELTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗High debt to equity ratio of 3.1x
- ✗Shares diluted 25.5% in last year
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 97.8x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ELTX Price & Volume
Elicio Therapeutics, Inc. (ELTX) stock price & volume — 10-year historical chart
Loading chart...
ELTX Growth Metrics
Elicio Therapeutics, Inc. (ELTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM23.75%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM40.42%
Return on Capital
10 Years-316.57%
5 Years-211.78%
3 Years-232.97%
Last Year-219.22%
ELTX Recent Earnings
Elicio Therapeutics, Inc. (ELTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
Mar 12, 2026EPS
$0.49
Est $0.47
-4.3%
Revenue
—
Q4 2025
Nov 13, 2025EPS
$0.60
Est $0.62
+3.2%
Revenue
—
Q3 2025
Aug 7, 2025EPS
$0.66
Est $0.69
+4.3%
Revenue
—
Q2 2025
May 13, 2025EPS
$0.87
Est $0.67
-29.9%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 12, 2026 | $0.49vs $0.47-4.3% | — |
| Q4 2025 | Nov 13, 2025 | $0.60vs $0.62+3.2% | — |
| Q3 2025 | Aug 7, 2025 | $0.66vs $0.69+4.3% | — |
| Q2 2025 | May 13, 2025 | $0.87vs $0.67-29.9% | — |
Based on last 12 quarters of dataView full earnings history →
ELTX Peer Comparison
Elicio Therapeutics, Inc. (ELTX) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 ADCT | 490.96M | 3.86 | -3.45 | 14.85% | -173.02% | |||
 IMCR | 1.56B | 30.73 | -57.98 | 20% | -4.88% | -4.83% | 0.11 | |
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 NVAX | 1.53B | 9.36 | 3.69 | 64.69% | -14.73% | |||
 MRNA | 19.35B | 48.79 | -6.72 | -39.23% | -143.55% | -36.73% | 0.22 | |
 BNTX | 23.94B | 95.26 | -18.00 | 0.2% | -39.6% | -6.03% | 0.01 |
Compare ELTX vs Peers
Elicio Therapeutics, Inc. (ELTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ELTX Income Statement
Elicio Therapeutics, Inc. (ELTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'13 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 6.58M | 4.03M | 1.49M | 2.88M | 28.31M | 0 | 0 | 0 | 0 |
| Revenue Growth % | -9.82% | -38.78% | -63.09% | 93.68% | 883.06% | -100% | - | - | - |
| Cost of Goods Sold | 3.17M | 380K | 1.14M | 1.82M | 1.23M | 1.06M | 1.17M | 1.18M | 0 |
| COGS % of Revenue | 48.22% | 9.43% | 76.4% | 63.13% | 4.36% | - | - | - | - |
| Gross Profit | 3.41M▲ 0% | 3.65M▲ 7.1% | 351K▼ 90.4% | 1.06M▲ 202.6% | 27.08M▲ 2449.7% | -1.06M▼ 103.9% | -1.17M▼ 10.7% | -1.18M▼ 0.7% | 0▲ 100.0% |
| Gross Margin % | 51.78% | 90.57% | 23.6% | 36.88% | 95.64% | - | - | - | - |
| Gross Profit Growth % | -5.97% | 7.08% | -90.38% | 202.56% | 2449.72% | -103.9% | -10.69% | -0.68% | 100% |
| Operating Expenses | 3.81M | 17.99M | 38.94M | 56.34M | 66.39M | 22.68M | 34.58M | 43.81M | 37.71M |
| OpEx % of Revenue | 57.82% | 446.54% | 2618.83% | 1956.08% | 234.48% | - | - | - | - |
| Selling, General & Admin | 3.61M | 8.84M | 9.15M | 17.46M | 17.78M | 5.63M | 11.9M | 11.33M | 12.81M |
| SG&A % of Revenue | 54.84% | 219.41% | 615.67% | 606.11% | 62.79% | - | - | - | - |
| Research & Development | 196.01K | 9.15M | 29.79M | 38.88M | 48.61M | 17.05M | 22.68M | 33.66M | 24.9M |
| R&D % of Revenue | 2.98% | 227.13% | 2003.16% | 1349.97% | 171.68% | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.18M | 0 |
| Operating Income | -397.8K▲ 0% | -14.34M▼ 3505.3% | -38.59M▼ 169.1% | -55.27M▼ 43.2% | -39.31M▲ 28.9% | -23.73M▲ 39.6% | -35.74M▼ 50.6% | -44.99M▼ 25.9% | -37.71M▲ 16.2% |
| Operating Margin % | -6.04% | -355.97% | -2595.23% | -1919.2% | -138.84% | - | - | - | - |
| Operating Income Growth % | 5.11% | -3505.33% | -169.08% | -43.23% | 28.89% | 39.62% | -50.61% | -25.85% | 16.16% |
| EBITDA | 62.54K | -14.34M | -38.09M | -54.65M | -38.51M | -22.68M | -34.58M | -43.81M | -37.71M |
| EBITDA Margin % | 0.95% | -355.92% | -2561.87% | -1897.4% | -136.01% | - | - | - | - |
| EBITDA Growth % | 42.16% | -23027.86% | -165.66% | -43.44% | 29.53% | 41.11% | -52.47% | -26.7% | 13.91% |
| D&A (Non-Cash Add-back) | 460.34K | 2K | 496K | 628K | 801K | 1.06M | 1.17M | 1.18M | 0 |
| EBIT | 2.03M | -20.02M | -40.66M | -71.26M | -52.73M | -24.61M | -34.14M | -51.44M | 0 |
| Net Interest Income | 0 | 0 | 81.48K | -8.85M | -873.05K | -3.53M | -686K | 322K | 0 |
| Interest Income | 0 | 252K | 81.48K | 0 | 3.39K | 64.83K | 373K | 777K | 776K |
| Interest Expense | 300.43K | 0 | 0 | 8.85M | 876.44K | 3.6M | 1.06M | 455K | -1.13M |
| Other Income/Expense | 2.13M | -5.68M | -2.07M | -24.83M | -15.27M | -4.47M | 550K | -6.91M | -1.86M |
| Pretax Income | 1.73M▲ 0% | -20.02M▼ 1255.9% | -40.66M▼ 103.0% | -80.11M▼ 97.0% | -54.57M▲ 31.9% | -28.21M▲ 48.3% | -35.2M▼ 24.8% | -51.9M▼ 47.5% | -39.57M▲ 23.8% |
| Pretax Margin % | 26.32% | -497.02% | -2734.23% | -2781.49% | -192.76% | - | - | - | - |
| Income Tax | 452.78K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 26.14% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | 632.24K▲ 0% | -20.02M▼ 3267.3% | -40.66M▼ 103.0% | -80.11M▼ 97.0% | -26.4M▲ 67.0% | -28.21M▼ 6.8% | -35.2M▼ 24.8% | -51.9M▼ 47.5% | -39.57M▲ 23.8% |
| Net Margin % | 9.61% | -497.02% | -2734.23% | -2781.49% | -93.25% | - | - | - | - |
| Net Income Growth % | 105.74% | -3267.3% | -103.04% | -97.03% | 67.04% | -6.85% | -24.77% | -47.46% | 23.75% |
| Net Income (Continuing) | 1.28M | -20.02M | -40.66M | -80.11M | -54.57M | -28.21M | -35.2M | -51.9M | -39.57M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 2.12M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 103.31▲ 0% | -6.79▼ 106.6% | -1.50▲ 77.9% | -1.93▼ 28.7% | -19.32▼ 901.0% | -9.10▲ 52.9% | -6.96▲ 23.5% | -4.25▲ 38.9% | -2.58▲ 39.3% |
| EPS Growth % | 105.76% | -106.57% | 77.91% | -28.67% | -901.04% | 52.9% | 23.52% | 38.94% | 39.29% |
| EPS (Basic) | 103.31 | -6.79 | -1.50 | -1.93 | -19.32 | -9.10 | -6.96 | -4.25 | -2.58 |
| Diluted Shares Outstanding | 6.12K | 2.95M | 8.15M | 8.15M | 3.2M | 3.1M | 5.06M | 12.2M | 15.31M |
| Basic Shares Outstanding | 6.12K | 2.95M | 8.15M | 8.15M | 3.2M | 3.1M | 5.06M | 12.2M | 15.31M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
ELTX Balance Sheet
Elicio Therapeutics, Inc. (ELTX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'13 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 2.62M | 25.68M | 6.11M | 40.32M | 91.25M | 10.72M | 16.35M | 20.69M | 19.31M |
| Cash & Short-Term Investments | 2.06M | 25.51M | 5.57M | 34.61M | 88.76M | 7.8M | 12.89M | 17.62M | 18.56M |
| Cash Only | 2.06M | 25.51M | 5.57M | 34.61M | 88.76M | 7.8M | 12.89M | 17.62M | 18.56M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 485.76K | 107K | 440K | 5M | 806K | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | 26.94 | 9.69 | 108 | 633.68 | 10.39 | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 60K | 95K | 360K | 379K | 36K | 895K | 1.28M | 748K |
| Total Non-Current Assets | 8.44M | 949K | 5.78M | 7.03M | 5.27M | 11.95M | 10.8M | 7.49M | 6.55M |
| Property, Plant & Equipment | 6.17M | 17K | 4.78M | 4.23M | 4.44M | 8.5M | 7.28M | 6.19M | 5.08M |
| Fixed Asset Turnover | 1.07x | 237.00x | 0.31x | 0.68x | 6.38x | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 1.67M | 932K | 999K | 822K | 723K | 617K | 0 | 696K | 0 |
| Other Non-Current Assets | 598.84K | 0 | 0 | 1.98M | 106K | 2.83M | 3.52M | 600K | 1.47M |
| Total Assets | 11.06M▲ 0% | 26.63M▲ 140.7% | 11.89M▼ 55.4% | 47.35M▲ 298.3% | 96.51M▲ 103.8% | 22.66M▼ 76.5% | 27.15M▲ 19.8% | 28.18M▲ 3.8% | 25.86M▼ 8.2% |
| Asset Turnover | 0.59x | 0.15x | 0.13x | 0.06x | 0.29x | - | - | - | - |
| Asset Growth % | 0.3% | 140.7% | -55.36% | 298.34% | 103.84% | -76.52% | 19.78% | 3.8% | -8.22% |
| Total Current Liabilities | 1.15M | 7.36M | 26.57M | 107.45M | 11.3M | 6.87M | 9.76M | 11.52M | 8.11M |
| Accounts Payable | 37.62K | 534K | 11.24M | 5.58M | 4.71M | 2.81M | 4.37M | 1.04M | 672K |
| Days Payables Outstanding | 4.33 | 512.92 | 3.61K | 1.12K | 1.39K | 968.61 | 1.36K | 321.62 | - |
| Short-Term Debt | 122.18K | 0 | 6.88M | 80.56M | 952K | 692K | 0 | 901K | 1.01M |
| Deferred Revenue (Current) | 82K | 19K | 0 | 3.94M | 2.3M | 1.44M | 0 | 1.17M | 0 |
| Other Current Liabilities | 905.11K | 6.8M | 6.35M | 14.21M | 3.33M | 444K | 2.57M | 2.31M | 7.1M |
| Current Ratio | 2.28x | 3.49x | 0.23x | 0.38x | 8.08x | 1.56x | 1.68x | 1.80x | 2.38x |
| Quick Ratio | 2.28x | 3.49x | 0.23x | 0.38x | 8.08x | 1.56x | 1.68x | 1.80x | 2.38x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 5.46M | 362K | 3.9M | 30.35M | 3.71M | 6.88M | 6.02M | 27.97M | 16.12M |
| Long-Term Debt | 5.2M | 0 | 0 | 635K | 0 | 0 | 0 | 20.03M | 4.09M |
| Capital Lease Obligations | 0 | 0 | 3.9M | 3.85M | 3.71M | 6.79M | 6.01M | 5.11M | 0 |
| Deferred Tax Liabilities | 4K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 250K | 0 | 0 | 0 | 0 | 92K | 11K | 2.83M | 12.02M |
| Total Liabilities | 6.6M | 7.72M | 30.47M | 137.8M | 15.01M | 13.75M | 15.77M | 39.49M | 24.23M |
| Total Debt | 5.32M | 0 | 10.78M | 85.04M | 4.66M | 7.48M | 6.92M | 26.04M | 5.11M |
| Net Debt | 3.27M | -25.51M | 5.21M | 50.44M | -84.09M | -316K | -5.98M | 8.42M | -13.46M |
| Debt / Equity | 1.19x | - | - | - | 0.06x | 0.84x | 0.61x | - | 3.12x |
| Debt / EBITDA | 85.13x | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 52.24x | - | - | - | - | - | - | - | - |
| Interest Coverage | -1.32x | - | - | -6.25x | -44.85x | -6.60x | -33.75x | -98.87x | - |
| Total Equity | 4.46M▲ 0% | 18.91M▲ 324.1% | -18.59M▼ 198.3% | -90.45M▼ 386.7% | 81.51M▲ 190.1% | 8.91M▼ 89.1% | 11.37M▲ 27.6% | -11.31M▼ 199.5% | 1.64M▲ 114.5% |
| Equity Growth % | 5.22% | 324.05% | -198.28% | -386.65% | 190.11% | -89.06% | 27.57% | -199.46% | 114.46% |
| Book Value per Share | 728.69 | 6.41 | -2.28 | -11.10 | 25.47 | 2.88 | 2.25 | -0.93 | 0.11 |
| Total Shareholders' Equity | 2.34M | 18.91M | -18.59M | -90.45M | 81.51M | 8.91M | 11.37M | -11.31M | 1.64M |
| Common Stock | 612 | 94K | 95K | 156K | 300K | 3K | 96K | 110K | 178K |
| Retained Earnings | 2.34M | -39.8M | -80.45M | -160.56M | -215.13M | -107.01M | -142.2M | -194.1M | -233.67M |
| Treasury Stock | 0 | -1.52M | -1.81M | -1.85M | 0 | 0 | -150K | -150K | 0 |
| Accumulated OCI | 0 | 0 | 0 | -333K | -103K | 0 | -197K | -175K | -127K |
| Minority Interest | 2.12M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ELTX Cash Flow Statement
Elicio Therapeutics, Inc. (ELTX) cash flow — operating, investing & free cash flow history
| Line item | Dec'13 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 1.89M | -8.02M | -24.59M | -22.89M | -23.94M | -22.18M | -32.69M | -37.07M | -36.95M |
| Operating CF Margin % | 28.75% | -199.06% | -1653.6% | -794.72% | -84.55% | - | - | - | - |
| Operating CF Growth % | 77.65% | -523.82% | -206.6% | 6.92% | -4.59% | 7.35% | -47.41% | -13.38% | 0.31% |
| Net Income | 632.24K | -20.02M | -40.66M | -80.11M | -26.4M | -28.21M | -35.2M | -51.9M | -39.57M |
| Depreciation & Amortization | 460.34K | 2K | 496K | 628K | 251.45K | 1.06M | 1.17M | 1.18M | 1.13M |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 617.76K | 579K | 1.18M | 1.45M | 2.7M |
| Deferred Taxes | -118K | 0 | 0 | 0 | 52.96K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.58M | 8.29M | 5.82M | 30.82M | 667.05K | 4.54M | 209K | 8.24M | -1.21M |
| Working Capital Changes | 332.64K | 3.09M | 9.75M | 25.77M | 872.43K | -150K | -57K | 3.96M | 0 |
| Change in Receivables | 94.62K | 180K | -333K | 440K | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -171.89K | 449K | -118K | -5.61M | 30.23K | 1.13M | 23K | -3.33M | -366K |
| Cash from Investing | -67.58K | 0 | -242K | -41K | -525.36K | -654K | -32K | -84K | -16K |
| Capital Expenditures | -17.57K | 0 | -242K | -41K | -525.36K | -654K | -66K | -87K | -16K |
| CapEx % of Revenue | 0.27% | - | 16.27% | 1.42% | 1.86% | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 34K | 3K | 0 |
| Cash from Financing | -1.17M | 31.74M | 4.89M | 52.41M | 19.39M | 21.2M | 38.61M | 42.32M | 36.7M |
| Debt Issued (Net) | 0 | 3.15M | 5.26M | 32.12M | 14.03M | 0 | 10M | 19.73M | 0 |
| Equity Issued (Net) | 0 | 1000K | -375K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | -375K | -36K | 0 | 0 | -150K | 0 | 0 |
| Other Financing | -1.17M | 0 | 0 | 0 | 314.88K | 82K | 21.76M | 16.96M | 36.7M |
| Net Change in Cash | 652.76K▲ 0% | 23.45M▲ 3493.2% | -19.94M▼ 185.0% | 29.04M▲ 245.6% | -5.07M▼ 117.5% | -1.63M▲ 67.8% | 5.89M▲ 460.9% | 5.19M▼ 11.8% | -225K▼ 104.3% |
| Free Cash Flow | 1.87M▲ 0% | -8.02M▼ 527.8% | -24.83M▼ 209.6% | -22.93M▲ 7.7% | -24.46M▼ 6.7% | -22.83M▲ 6.7% | -32.76M▼ 43.5% | -37.16M▼ 13.4% | -36.97M▲ 0.5% |
| FCF Margin % | 28.49% | -199.06% | -1669.87% | -796.15% | -86.41% | - | - | - | - |
| FCF Growth % | 84.26% | -527.79% | -209.61% | 7.66% | -6.7% | 6.67% | -43.48% | -13.42% | 0.5% |
| FCF per Share | 306.33 | -2.72 | -3.05 | -2.81 | -7.65 | -7.37 | -6.48 | -3.04 | -2.41 |
| FCF Conversion (FCF/Net Income) | 2.99x | 0.40x | 0.60x | 0.29x | 0.91x | 0.79x | 0.93x | 0.71x | 0.93x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ELTX Key Ratios
Elicio Therapeutics, Inc. (ELTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2012 | 2013 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 7.25% | 14.54% | -171.37% | -25020.31% | - | -32.39% | -62.39% | -346.95% | -170157.38% | -2418.77% |
| Return on Invested Capital (ROIC) | -3.8% | -3.73% | -1910.8% | - | - | - | -592.14% | -383.12% | -2692.7% | - |
| Gross Margin | 49.66% | 51.78% | 90.57% | 23.6% | 36.88% | 95.64% | - | - | - | - |
| Net Margin | 4.21% | 9.61% | -497.02% | -2734.23% | -2781.49% | -93.25% | - | - | - | - |
| Debt / Equity | 1.28x | 1.19x | - | - | - | 0.06x | 0.84x | 0.61x | - | 3.12x |
| Interest Coverage | -1.36x | -1.32x | - | - | -6.25x | -44.85x | -6.60x | -33.75x | -98.87x | - |
| FCF Conversion | 3.47x | 2.99x | 0.40x | 0.60x | 0.29x | 0.91x | 0.79x | 0.93x | 0.71x | 0.93x |
| Revenue Growth | - | -9.82% | -38.78% | -63.09% | 93.68% | 883.06% | -100% | - | - | - |
ELTX SEC Filings & Documents
Elicio Therapeutics, Inc. (ELTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
ELTX Frequently Asked Questions
Elicio Therapeutics, Inc. (ELTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Elicio Therapeutics, Inc. (ELTX) grew revenue by 0.0% over the past year. Growth has been modest.
Elicio Therapeutics, Inc. (ELTX) reported a net loss of $39.6M for fiscal year 2025.
Dividend & Returns
Elicio Therapeutics, Inc. (ELTX) has a return on equity (ROE) of -2418.8%. Negative ROE indicates the company is unprofitable.
Elicio Therapeutics, Inc. (ELTX) had negative free cash flow of $37.0M in fiscal year 2025, likely due to heavy capital investments.
Explore More ELTX
Elicio Therapeutics, Inc. (ELTX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates